105 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
16
Elimination of antibacterial activities of non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists derived from erythromycin A.
Abbott Laboratories
4
GnRH antagonists: the promise of treating sex-hormone-related diseases.
Therachem Research Medilab (India)
4
Synthesis and in vitro evaluation of small-molecule [18F] labeled gonadotropin-releasing hormone (GnRH) receptor antagonists as potential PET imaging agents for GnRH receptor expression.
Norwegian Medical Cyclotron Centre
4
Influences of hydrocarbon linkers on the receptor binding affinities of gonadotropin-releasing hormone peptides.
University of New Mexico
4
Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates.
TBA
25
Nonpeptide luteinizing hormone-releasing hormone antagonists derived from erythromycin A: design, synthesis, and biological activity of cladinose replacement analogues.
Abbott Laboratories
37
Active reduced-size hexapeptide analogues of luteinizing hormone-releasing hormone.
Abbott Laboratories
16
5-Aryluracils as potent GnRH antagonists-Characterization of atropisomers.
Neurocrine Biosciences
28
Synthesis and evaluation of homodimeric GnRHR antagonists having a rigid bis-propargylated benzene core.
Leiden University
16
The use of ligand-based de novo design for scaffold hopping and sidechain optimization: two case studies.
Neurocrine Biosciences
45
Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
Takeda Pharmaceutical
31
Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
Salk Institute
33
Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.
Salk Institute
44
Synthesis and structure-activity relationships of 1-arylmethyl-5-aryl-6-methyluracils as potent gonadotropin-releasing hormone receptor antagonists.
Neurocrine Biosciences
26
Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
Takeda Chemical Industries
36
GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6.
Ferring Research Institute
7
Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor.
Takeda Chemical Industries
21
Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor.
Takeda Pharmaceutical
22
Design, synthesis, and evaluation of novel 3,6-diaryl-4-aminoalkoxyquinolines as selective agonists of somatostatin receptor subtype 2.
Merck Research Laboratories
13
Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor.
Wyeth Research
9
Discovery of 6-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): an orally active antagonist of the gonadotropin releasing hormone receptor (GnRH-R).
Wyeth Research
31
Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: structure-activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template.
Wyeth Research
13
Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor.
Neurocrine Biosciences
24
Zwitterionic uracil derivatives as potent GnRH receptor antagonists with improved pharmaceutical properties.
Neurocrine Biosciences
20
2-phenyl-4-piperazinylbenzimidazoles: orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor.
Wyeth Research
25
Potent and orally bioavailable zwitterion GnRH antagonists with low CYP3A4 inhibitory activity.
Neurocrine Biosciences
53
Non-peptide gonadotropin-releasing hormone receptor antagonists.
Neurocrine Biosciences
3
Novel non-peptide uracil-derived human gonadotropin-releasing hormone receptor antagonists.
University of Milan
27
Synthesis and structure-activity relationships of thieno[2,3-b]pyrroles as antagonists of the GnRH receptor.
AstraZeneca
59
Selection, synthesis, and structure-activity relationship of tetrahydropyrido[4,3-d]pyrimidine-2,4-diones as human GnRH receptor antagonists.
Neurocrine Biosciences
26
Identification of 2-(4,5,6,7-tetrahydro-1H-pyrrolo[3,2-c]pyridin-3-yl)-ethylamine derivatives as novel GnRH receptor antagonists.
Neurocrine Biosciences
22
Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
Salk Institute
11
Discovery of the thieno[2,3-d]pyrimidine-2,4-dione derivative 21a: A potent and orally bioavailable gonadotropin-releasing hormone receptor antagonist.
Yantai University
10
Determination of the binding mode of thienopyrimidinedione antagonists to the human gonadotropin releasing hormone receptor using structure-activity relationships, site-directed mutagenesis, and homology modeling.
Neurocrine Biosciences
1
Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
Pfizer
5
Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.
Neurocrine Biosciences
30
Structure-activity relationships of 1,3,5-triazine-2,4,6-triones as human gonadotropin-releasing hormone receptor antagonists.
Neurocrine Biosciences
10
Synthesis, in vivo and in vitro biological activity of novel azaline B analogs.
Salk Institute
28
Uracils as potent antagonists of the human gonadotropin-releasing hormone receptor without atropisomers.
Neurocrine Biosciences
46
Benzimidazoles as non-peptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 3: Discovery of 1-(1H-benzimidazol-5-yl)-3-tert-butylurea derivatives.
Kyoto 619-0216
57
3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization.
Neurocrine Biosciences
12
Efficient synthesis of bicyclic oxazolino- and thiazolino[3,2-c]pyrimidine-5,7-diones and its application to the synthesis of GnRH antagonists.
Neurocrine Biosciences
22
Benzimidazole derivatives as novel nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 2: Benzimidazole-5-sulfonamides.
Kyoto 619-0216
22
Benzimidazole derivatives as novel nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists. Part 1: Benzimidazole-5-sulfonamides.
Kyoto 619-0216
11
A convenient one-pot synthesis of asymmetric 1,3,5-triazine-2,4,6-triones and its application towards a novel class of gonadotropin-releasing hormone receptor antagonists.
Neurocrine Biosciences
16
Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists.
Merck Research Laboratories
31
Synthesis and structure-activity relationships of uracil derived human GnRH receptor antagonists: (R)-3-[2-(2-amino)phenethyl]-1-(2,6-difluorobenzyl)-6-methyluracils containing a substituted thiophene or thiazole at C-5.
Neurocrine Biosciences
26
3-(2-aminoalkyl)-1-(2,6-difluorobenzyl)-5- (2-fluoro-3-methoxyphenyl)-6-methyl-uracils as orally bioavailable antagonists of the human gonadotropin releasing hormone receptor.
Neurocrine Biosciences
26
Synthesis and structure-activity relationships of (R)-1-alkyl-3-[2-(2-amino)phenethyl]-5-(2-fluorophenyl)-6-methyluracils as human GnRH receptor antagonists.
Neurocrine Biosciences
15
Syntheses and structure-activity relationship studies of piperidine-substituted quinolones as nonpeptide gonadotropin releasing hormone antagonists.
Merck
27
Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidine-2,4-dione derivatives as potent GnRH receptor antagonists.
Neurocrine Biosciences
1
Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer.
University of Ioannina
2
Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues.
Institute of Science
29
Synthesis and structure-activity relationships of 1-arylmethyl-3-(1-methyl-2-amino)ethyl-5-aryl-6-methyluracils as antagonists of the human GnRH Receptor.
Neurocrine Biosciences
28
Synthesis and structure-activity relationships of 1-arylmethyl-3-(2-aminopropyl)-5-aryl-6-methyluracils as potent GnRH receptor antagonists.
Neurocrine Biosciences
17
Identification of 1-arylmethyl-3- (2-aminoethyl)-5-aryluracil as novel gonadotropin-releasing hormone receptor antagonists.
Neurocrine Biosciences
28
Design and structure-activity relationships of 2-alkyl-3-aminomethyl-6-(3-methoxyphenyl)-7-methyl-8-(2-fluorobenzyl)imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists.
Neurocrine Biosciences
27
Characterization of mono- and diaminopyrimidine derivatives as novel, nonpeptide gonadotropin releasing hormone (GnRH) receptor antagonists.
Agouron Pharmaceuticals
8
A novel synthesis of 7-aryl-8-fluoro-pyrrolo[1,2-a]pyrimid-4-ones as potent, stable GnRH receptor antagonists.
Neurocrine Biosciences
24
The discovery of novel small molecule non-peptide gonadotropin releasing hormone (GnRH) receptor antagonists.
Agouron Pharmaceuticals
18
Modification of the pyridine moiety of non-peptidyl indole GnRH receptor antagonists.
Merck Research Laboratories
22
Design, synthesis and structure-activity relationships of novel imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists.
Neurocrine Biosciences
19
Synthesis and initial structure-activity relationships of a novel series of imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists.
Neurocrine Biosciences
11
A new class of potent nonpeptide luteinizing hormone-releasing hormone (LHRH) antagonists: design and synthesis of 2-phenylimidazo[1,2-a]pyrimidin-5-ones.
Takeda Chemical Industries
38
2-Arylindoles as gonadotropin releasing hormone (GnRH) antagonists: optimization of the tryptamine side chain.
Merck Research Laboratories
30
A novel synthesis of 2-arylpyrrolo[1,2-a]pyrimid-7-ones and their structure-activity relationships as potent GnRH receptor antagonists.
Neurocrine Biosciences
32
Initial structure-activity relationship studies of a novel series of pyrrolo[1,2-a]pyrimid-7-ones as GnRH receptor antagonists.
Neurocrine Biosciences
41
Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women.
Bayer
4
Design, synthesis, and evaluation of a long-acting, potent analogue of gonadotropin-releasing hormone.
Institute of Science
29
Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity.
Merck Research Laboratories
51
Potent nonpeptide GnRH receptor antagonists derived from substituted indole-5-carboxamides and -acetamides bearing a pyridine side-chain terminus.
Merck Research Laboratories
38
Substituted indole-5-carboxamides and -acetamides as potent nonpeptide GnRH receptor antagonists.
Merck Research Laboratories
24
Heterocyclic derivatives of 2-(3,5-dimethylphenyl)tryptamine as GnRH receptor antagonists.
Merck Research Laboratories
14
2-(3,5-Dimethylphenyl)tryptamine derivatives that bind to the GnRH receptor.
Merck Research Laboratories
1
A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptor.
Merck Research Laboratories
20
SAR studies of novel 5-substituted 2-arylindoles as nonpeptidyl GnRH receptor antagonists.
Merck Research Laboratories
40
Initial structure-activity relationship of a novel class of nonpeptidyl GnRH receptor antagonists: 2-arylindoles.
Merck Research Laboratories
31
Design and synthesis of potent hexapeptide and heptapeptide gonadotropin-releasing hormone antagonists by truncation of a decapeptide analogue sequence.
Institute of Science
11
Structure-activity studies of reduced-size gonadotropin-releasing hormone agonists derived from the sequence of an endothelin antagonist.
Institute of Science
56
Quinolones as gonadotropin releasing hormone (GnRH) antagonists: simultaneous optimization of the C(3)-aryl and C(6)-substituents.
Merck Research Laboratories
134
Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist.
Sk Chemicals
26
Potent antagonists of gonadotropin releasing hormone receptors derived from quinolone-6-carboxamides.
Merck Research Laboratories
5
Consensus bioactive conformation of cyclic GnRH antagonists defined by NMR and molecular modeling.
Salk Institute
46
Design of potent dicyclic (1-5/4-10) gonadotropin releasing hormone (GnRH) antagonists.
Salk Institute
27
Design of monocyclic (1-3) and dicyclic (1-3/4-10) gonadotropin releasing hormone (GnRH) antagonists.
Salk Institute
38
Design of potent dicyclic (4-10/5-8) gonadotropin releasing hormone (GnRH) antagonists.
Salk Institute
8
Investigation of the 4-O-alkylamine substituent of non-peptide quinolone GnRH receptor antagonists.
Merck Research Laboratories
22
Identification and initial structure-activity relationships of a novel non-peptide quinolone GnRH receptor antagonist.
Merck Research Laboratories
51
In vitro and in vivo activities of reduced-size antagonists of luteinizing hormone-releasing hormone.
Tap Pharmaceuticals
7
The effect of NMeTyr5 substitution in luteinizing hormone-releasing hormone antagonists.
Abbott Laboratories
10
LH-RH antagonists: design and synthesis of a novel series of peptidomimetics.
Abbott Laboratories
43
Synthesis and biological evaluation of 3-(2-aminoethyl) uracil derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.
Tiumbio
17
Novel gonadotropin-releasing hormone antagonists: peptides incorporating modified N omega-cyanoguanidino moieties.
Salk Institute
7
Gonadotropin-releasing hormone antagonists with N omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6.
Salk Institute
27
FUSED BICYCLIC SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF
Triana Biomedicines
3
OXA-IBOGAINE ANALOGUES FOR TREATMENT OF SUBSTANCE USE DISORDERS
Columbia University
48
Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
Indiana University Research and Technology
55
Identification of Inhibitors of PvdQ, an Enzyme Involved in the Synthesis of the Siderophore Pyoverdine.
The Broad Institute , Cambridge, Massachusetts 02142, United States